关于为全资子公司提供担保的进展公告 （一）担保的基本情况 为满足河南翔宇医疗设备股份有限公司（以下简称"公司"）全资子公司河南瑞贝塔医疗科技有限公司 （以下简称"瑞贝塔"）的建设发展规划和实际生产经营需要，公司于近日与华夏银行股份有限公司郑州 分行（以下简称"债权人"）签署了《最高额保证合同》，约定由公司为瑞贝塔向债权人申请的总额不超 过人民币10,000.00万元的贷款提供连带责任担保。本次担保无反担保。 （二）内部决策程序 证券代码：688626 证券简称：翔宇医疗 公告编号：2025-058 河南翔宇医疗设备股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 担保对象及基本情况 公司于2025年11月14日召开第三届董事会第八次会议，审议并全票通过了《关于为全资子公司提供担保 的议案》，同意公司为瑞贝塔提供担保总额度不超过40,000.00万元的不可撤销连带责任担保。根据《上 海证券交易所科创板股票上市规则》《公司章程》等相关规定，以上审议事项在公司董事会审批权限范 围内，无需提交公司股东会 ...

证券日报网讯12月10日晚间，翔宇医疗发布公告称，截至本公告披露日，公司不存在逾期担保情况或涉 及诉讼的担保情况。 ...

证券代码：688626 证券简称：翔宇医疗 公告编号：2025-058 河南翔宇医疗设备股份有限公司 关于为全资子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | | 次担保金额） | | 预计额度内 | 否有反担保 | | --- | --- | --- | --- | --- | --- | | 被担保人名称 河南瑞贝塔医疗 科技有限公司 | 本次担保金额 10,000.00万元 | 实际为其提供的 担保余额（含本 10,000.00 | 万元 | 是否在前期 是 | 本次担保是 否 | 累计担保情况 | 对外担保逾期的累计金额（万元） | 0.00 | | --- | --- | | 截至本公告日上市公司及其控股子公 | | | 司对外担保总额（万元）（含本次担保 | 10,000.00 | | 金额） | | | 对外担保总额占上市公司最近一期经 | 4.91 | | 审计净资产的比例（%） | | | 特别风险提示（如有请勾选） | □担保金额（含本次 ...

资料显示，元枢智能医疗科技（厦门）有限责任公司成立于2025年12月3日，法定代表人为赵雪贝，注 册资本1000万人民币，公司位于厦门市，技术服务、技术开发、技术咨询、技术交流、技术转让、技术 推广、可穿戴智能设备制造、第二类医疗器械销售、第二类医疗设备租赁、货物进出口、技术进出口、 人工智能行业应用系统集成服务、智能机器人的研发、智能机器人销售、人工智能硬件销售、人工智能 双创服务平台、人工智能应用软件开发、人工智能基础软件开发、人工智能基础资源与技术平台、工业 控制计算机及系统制造、信息系统集成服务、信息技术咨询服务、体育健康服务、大数据服务、互联网 数据服务、健康咨询服务（不含诊疗服务）、电气设备销售、电子专用设备制造、电子产品销售、机械 设备研发、计算机软硬件及辅助设备零售、计算机软硬件及外围设备制造、电子测量仪器制造、电子测 量仪器销售、第一类医疗器械销售、第一类医疗设备租赁、第一类医疗器械生产、国内贸易代理、贸易 经纪、供应链管理服务。（除依法须经批准的项目外，凭营业执照依法自主开展经营活动）许可项目： 第二类医疗器械生产、第三类医疗器械生产、第三类医疗器械经营、第三类医疗设备租赁、互联网信息 服 ...

Core Viewpoint - Yuanxu Intelligent Medical Technology (Xiamen) Co., Ltd. has been established with a registered capital of 10 million yuan, focusing on various applications in the artificial intelligence sector [1] Company Summary - The company is wholly owned by Xiangyu Medical [1] - Its business scope includes artificial intelligence industry application system integration services, research and development of intelligent robots, sales of intelligent robots, sales of artificial intelligence hardware, and services for the artificial intelligence innovation and entrepreneurship platform [1]

Core Viewpoint - The demand for medium-frequency therapeutic devices in China is significantly increasing due to the aging population and the growing need for postoperative rehabilitation and chronic disease treatment, with a notable rise in market demand driven by enhanced health awareness among the public [1][7]. Market Overview - The medium-frequency therapeutic device, also known as low-frequency modulated medium-frequency therapeutic device, operates on the principle of medium-frequency electrotherapy, which is effective in disease treatment, pain relief, and rehabilitation care [1][5]. - The total procurement volume of medium-frequency therapeutic devices in China is projected to reach 6,745 units in 2024, representing a year-on-year increase of 37.26%, with a total procurement amount of 0.76 billion yuan, up 1.33% year-on-year [1][7]. Market Policy - The Chinese government emphasizes the development of the medical device industry, including medium-frequency therapeutic devices, through various policies aimed at regulating market order, ensuring product quality, and safeguarding patient safety [4][5]. Industry Chain - The upstream of the medium-frequency therapeutic device industry includes suppliers of electronic components such as control chips and power amplifiers, while the midstream involves R&D, design, and production [5]. - The downstream demand structure shows that medical institutions account for over 50% of the demand, with orthopedic and neurological rehabilitation being the core application areas [5][6]. Competitive Landscape - The market concentration for medium-frequency therapeutic devices in China is high, with the top five companies holding a market share of 55.66% as of the first half of 2025. Xiangyu Medical leads with a market share of 15.39% [8]. - Xiangyu Medical reported a total revenue of 744 million yuan in 2024, with 67.79% coming from rehabilitation therapy equipment [9]. - Beiyikang, another key player, achieved a revenue of 115 million yuan in the first half of 2025, with 84.98% from rehabilitation technology products [10]. Development Trends - The future of medium-frequency therapeutic devices will focus on smart technology integration, including AI algorithms for personalized treatment and IoT for data sharing and remote monitoring [11]. - The application scenarios for these devices are expected to expand beyond traditional medical settings to include sports rehabilitation and wellness, targeting specific user groups such as office workers and fitness enthusiasts [11].

Core Viewpoint - Neihuang County is committed to becoming a technology-driven and industry-strong county, focusing on three major industrial clusters: ceramics, rehabilitation equipment, and agricultural machinery, aiming for high-quality development and advanced manufacturing in Central China [1][2][3] Group 1: Ceramics Industry - Neihuang County's ceramics industry park houses 12 key ceramic enterprises and 20 modern production lines, with an annual output of 46.5 million square meters of tiles, making it the largest and most diverse ceramic production base in the Central China region [1] - The county has invested 1.33 billion yuan in upgrading environmental facilities, emphasizing "intelligent transformation and green upgrading" as key strategies for industry transition [1][2] Group 2: Rehabilitation Equipment - The rehabilitation equipment sector has established a complete industrial chain with 62 upstream and downstream enterprises, supported by a total investment of 2.5 billion yuan in the rehabilitation equipment industrial park [2] - A national-level testing center for rehabilitation medical devices has been established, equipped with over 1,000 advanced devices capable of conducting more than 2,000 tests, providing one-stop testing services for enterprises [2] Group 3: Agricultural Machinery - Neihuang County is actively integrating into the provincial "7+28+N" key industrial chain system to cultivate new growth points in agricultural machinery manufacturing [2] - A rapidly developing agricultural machinery industrial park with a total investment of 3 billion yuan is expected to produce 50,000 tractors annually, with projects like large combine harvester assembly and new seeders already in production [2] Group 4: Technological Innovation - The county is focusing on high-quality development and new productive forces as core engines for economic advancement, aligning with strategic directives from higher-level government meetings [3] - The county aims to enhance the synergy between technological innovation and industrial innovation to accelerate the growth and vitality of new productive forces [3]

人民财讯11月30日电，11月29日，翔宇医疗与湖南省康复医学会、邵阳学院附属第一医院康复医学科共 建的脑机接口临床研究与转化创新分中心启动仪式在医院多功能厅顺利举行。目前，翔宇医疗脑机接口 —上下肢主被动康复训练仪、脑机接口—吞咽神经和肌肉电刺激仪等系列设备已进入医院病房。 转自：证券时报 ...

Core Viewpoint - The company is cautiously advancing its investment and acquisition efforts in the rehabilitation medical device industry, focusing on external growth through integration and partnerships, despite recent declines in revenue and profit [1][2][3] Group 1: Financial Performance - Since its listing in 2021, the company's revenue and net profit peaked in 2023 but began to decline thereafter, with a projected revenue of 744 million yuan in 2024, down 0.17% year-on-year, and a net profit of 103 million yuan, down 54.68% year-on-year [2] - For the first three quarters of 2025, the company reported a revenue of 537 million yuan, a year-on-year increase of 6.00%, but a net profit of 44 million yuan, down 40.09% year-on-year, primarily due to increased sales and R&D expenses [3] Group 2: Research and Development Focus - The company is increasing its R&D investment, with a total of 140 million yuan in R&D for the first three quarters of 2025, a year-on-year increase of 34.69%, representing 26.11% of revenue, up 5.56 percentage points year-on-year [3] - The company is focusing its R&D efforts on rehabilitation robots and brain-computer interface technologies, with significant projects approved in the field of elderly care, including a specialized bathing robot [4][5] Group 3: Strategic Projects - The company is leading a project for the development and application of a specialized bathing robot for home care, aiming to improve safety, comfort, and cleanliness for bedridden elderly individuals [4] - The company has established a brain-computer interface laboratory and is integrating this technology into its rehabilitation products, which is expected to enhance recovery outcomes for patients [5]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688626 证券简称：翔宇医疗公告编号：2025-056 河南翔宇医疗设备股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本次会议是否有被否决议案：无 一、会议召开和出席情况 （一）股东大会召开的时间：2025年11月24日 （二）股东大会召开的地点：河南省安阳市内黄县帝喾大道中段公司会议室 （三）出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及其持有表决权数量的情 况： ■ 注：公司表决权数量不含截至股权登记日公司已回购股份的数量。 （四）表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次股东大会由公司董事会召集，由董事长何永正先生主持，会议以现场投票和网络投票相结合的方式 进行表决。本次会议的召集、召开及表决方式符合《公司法》、《证券法》、《公司章程》等的规定。 （五）公司董事、监事和董事会秘书的出席情况 1、公司在任董事5人，现场出席5人； 2、公司在任监事 ...